International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations
Adam S. Kittai(Icahn School of Medicine at Mount Sinai), Paolo Ghia(Vita-Salute San Raffaele University), Rebecca L. King(Mayo Clinic in Arizona), Maurilio Ponzoni(San Raffaele University of Rome), José I. Martín‐Subero(Institució Catalana de Recerca i Estudis Avançats), Stephan Stilgenbauer(Universität Ulm), Constantine S. Tam(The Alfred Hospital), Elisa ten Hacken(Harvard University), Paul J. Hampel(Mayo Clinic), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Erin M. Parry(Broad Institute), Ohad Benjamini(Sheba Medical Center), Toby A. Eyre(Oxford University Hospitals NHS Trust), Carolyn Owen(University of Calgary), Rodney J. Hicks(Flinders Medical Centre), Matthew S. Davids(Dana-Farber Cancer Institute), Arnon P. Kater(Amsterdam University Medical Centers), Alexey V. Danilov(City of Hope), Anna Maria Frustaci(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Michael Hallek(Integrated Oncology (United States)), Monia Marchetti(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo), Philip A. Thompson(The Royal Melbourne Hospital), Othman Al‐Sawaf(Integrated Oncology (United States)), Yair Herishanu(Tel Aviv University), William G. Wierda(The University of Texas MD Anderson Cancer Center), Tanya Siddiqi(City Of Hope National Medical Center), Barbara Eichhorst, Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 14
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k